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activities of WT-MBNL1 and MBNL1 (1-2, 1-2). Preliminary results showed that 
MBNL1 (1-2, 1-2) had similar splicing activity compared to the wild type MBNL1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
iv  
 
Acknowledgements 
I would like to express my utmost gratitude to Professor Berglund for offering 
me the privilege to explore meaningful scientific research, as well as entrusting me to 
work independently. I would also like to thank Melissa Hale for her guidance and 
mentorship throughout my research because without her none of this would have been 
possible. Thank you Berglund lab for all of your help. Finally, I would like to thank my 
family for their unconditional love and support. 
. 
  
  
v  
 
Table of Contents 
INTRODUCTION 1 
Alternative splicing 1 
Myotonic dystrophy pathology 3 
Muscleblind-like 1 (MBNL1) 4 
Background experiments hint towards the possibility of an RNA-binding  
protein with increased affinity and activity 7 
 
METHODS 12 
Cell culture and transfection 13 
Western blot analysis 14 
Cell-based splicing assay 14 
 
RESULTS 16 
Western blot analysis confirms successful dosing 16 
Both WT-MBNL1 and MBNL1 (1-2, 1-2) exhibit a splicing sensitivity response 19 
 
DISCUSSION 23 
Western blot analysis and splicing assay results confirm successful dosing  
simulation       23 
Applications and advantages of this dosage simulation model                     
(transfection titration) 23 
Challenges faced in developing the transfection titration model 25 
 
FUTURE DIRECTIONS AND REFINEMENT 28 
 
REFERENCES 30 
 
 
  
  
vi  
List of Figures  
Figure 1: Splicing and assembly of the spliceosome   3 
 
Figure 2: Cassette exon alternative splicing event and possible products                        4                                         
 
Figure 3: MBNL1 co-localizes with CUG repeat RNA and forms nuclear foci in 
neurons of DM1 patients                                                                                                   5 
 
Figure 4: Schematic representation of MBNL1's structure including sequence  
alignment and crystal structure of the zinc finger domains                                               7 
 
Figure 5: Graphic representation of the two constructed MBNL1 variants                   9 
 
Figure 6: Workflow illustration of a transfection titration cell-based splicing assay     13 
 
Figure 7: MBNL1 (1-2, 1-2) is expressed at low levels in an overexpression system   17 
 
Figure 8: Qualitative and quantitative confirmation of a successful dosing system      18 
 
Figure 9: Splicing activity response to both constructs as a function of plasmid 
concentration                                                                                                                   21 
 
 
 
 
  
  
vii  
List of Tables  
 
Table 1: MBNL1 (1-2, 1-2) shows similar splicing activity in comparison to WT-
MBNL1 12 
 
 
  
  
INTRODUCTION 
Alternative splicing 
Genes contain all genetic information necessary for cell survival in the form of 
DNA. Each gene encodes instructions to create and assemble proteins. These proteins 
are directly responsible for performing cellular functions vital for cell viability. In order 
to produce proteins from the corresponding DNA, a complex and highly regulated 
process must be carried out. First, DNA is converted into pre-mRNA through 
transcription. The pre-mRNA contains important coding regions of the protein called 
exons as well as untranslated regions referred to as introns. Before translation into 
protein, pre-mRNA is processed into mature RNA, commonly referred to as messenger 
RNA (mRNA). One of these processing steps is splicing. Splicing is a key process in 
which introns are removed from the pre-mRNA and the remaining exons are stitched 
together (Figure 1) 1.  
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One of many specialized splicing events is alternative splicing. Alternative 
splicing allows the cell to select which exons are ultimately included or excluded in the 
final processed mRNA, which in turn dictates which protein isoform is produced 
(Figure 2)2. Why is alternative splicing so important? Alternative splicing enables cells 
to express multiple protein isoforms from the same gene, thus generating increased 
protein diversity. A diverse proteome (entire set of proteins expressed by a genome) is 
critical in regulating gene expression both temporally and spatially3. Therefore, 
alternative splicing offers a method for regulating what protein isoforms are produced 
across various tissues and throughout development. It is estimated that over 90 percent 
Figure 1. Splicing and the 
assembly of the spliceosome. 
Pre-mRNA with intronic 
sequences (thin line) and exonic 
sequences (coloured boxes) is 
represented above with the 
consensus sequences at the intron 
5′ and 3′ ends (Y represents 
pyrimidines, N represents any 
nucleotide). The branch point 
adenosine is represented in bold. 
Many cis-elements and factors 
assist in the assembly of the 
spliceosome. The spliceosome is 
assembled sequentially forming 
the complexes illustrated. Once 
assembled, the splicing reaction 
is catalyzed, generating a mature 
RNA and releasing the intron in a 
lariat conformation. Box 1. 
BPRS, branch point recognition 
sequence; SF1, splicing factor 1; 
ss, splice site; U2AF, auxiliary 
factor, U2 snRNP (small nuclear 
ribonucleoprotein) (nature 
reviews 2012) 1. 
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of human genes are alternatively 
spliced4. As such, the mis-
regulation of alternative splicing, 
which can produce a dramatic 
shift in the potential protein 
isoforms expressed, can prove 
disastrous for the cell. Disease-
like symptoms may develop as a 
consequence of aberrant splicing. 
It is estimated that over 50 
percent of all diseases contain a 
mis-regulated splicing element5. 
Mis-regulation of alternative splicing plays a pivotal role in myotonic dystrophy Type 1 
(DM1) pathology. 
Myotonic dystrophy pathology 
Myotonic dystrophy (type 1) is the most common form of adult-onset muscular 
dystrophy affecting one in every 8,000 individuals. Those afflicted with DM1 can 
experience a wide range of symptoms that occur within multiple systems of the body. 
Varying in severity, these symptoms include myotonia (hyperexcitability of skeletal 
muscle), muscle wasting, insulin resistance, cardiac defects, cataracts, and cognitive 
dysfunction5. Pathology of DM1 is highly studied and relatively well understood. DM1 
is characterized by a CTG trinucleotide repeat expansion located within the 3’ 
untranslated region of the DMPK (dystrophia myotonica protein kinase) gene5. Upon 
Figure 2. Cassette exon alternative splicing event. In a 
cassette exon event, the alternatively spliced exon is either 
included or “skipped.” The pre-mRNA transcript is shown in 
the middle. Constitutively spliced exons are shown as grey 
boxes and the alternatively spliced exon is shown as a white 
box. The line represents introns. Two different mRNAs may 
be generated, one in which the exon is included and one in 
which the exon is excluded. As a result, two different protein 
isoforms can be produced2. 
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transcription, the CTG repeats in DNA are converted into CUG repeats in RNA. 
Consequentially, the CUG repeats act as toxic RNA. These CUG repeats sequester the 
alternative splicing factor MBNL1 (MBNL1 is discussed in detail on pages 5-7) 7. 
MBNL1’s high affinity for YGCY (UGCU) sequences in the toxic RNA is responsible 
for the formation of nuclear foci (a combination of toxic RNA and proteins in the 
nucleus) (Figure 3) 8.   
The co-localization of MBNL1 and toxic CUG-repeat RNA effectively reduces 
the concentration of free MBNL1 within the cell. If MBNL1 is bound to the toxic RNA, 
it is unable to perform its primary regulatory function. Aberrant splicing of MBNL1’s 
pre-mRNA targets is responsible for a DM1 phenotype. 
Muscleblind-like 1 (MBNL1) 
Muscleblind-like protein 1 (MBNL1) is involved in numerous cellular processes 
including mRNA localization, cell fate, and most importantly, alternative splicing. 
MBNL1 is a master splicing regulator that promotes both exon inclusion and exclusion 
events, acting as a splicing enhancer or repressor9. As an alternative splicing regulator, 
MBNL1 is involved in the alternative splicing of numerous pre-mRNA transcripts 
including its own. For instance, MBNL1 promotes insulin receptor exon 11 inclusion10, 
Figure 3. MBNL1 co-localizes with CUG repeat RNA in the nucleus of neurons in 
DM1 patients, forming foci. CUG repeats are shown in red (visualized via 
fluorescent in situ hybridization, FISH), MBNL1 protein is shown in green 
(visualized via immunofluorescence), and DAP1 (fluorescent DNA stain) in blue. 
No foci or co-localization is observed from non-DM1 individuals8. 
 
 
5  
skeletal muscle chloride channel exon 7A exclusion11, and exon 5 exclusion of its own 
pre-mRNA transcript (among many others) 12.  
The mechanism through which MBNL1 regulates alternative splicing has yet to 
be deduced. One possible mechanistic explanation revolves around the idea that 
MBNL1 inhibits splicing by directly interfering with the splicing machinery upon 
binding its pre-mRNA transcripts. Recent work has shown that MBNL1 competes 
directly with the essential splicing factor U2AF65 (a splicing factor involved in the 
recruitment of a snRNP necessary for spliceosome assembly) (Figure 1) during the 
MBNL1-mediated splicing event of exon 5 in the cardiac troponin T pre-mRNA. When 
U2AF65 is prevented from binding the pre-mRNA, the U2 snRNP can no longer be 
recruited in the formation of the spliceosome and the following exon 5 is excluded13. 
Although this is only one example of an alternative splicing event, the general 
consensus follows that MBNL1’s splicing activity is dependent on its ability to bind its 
pre-mRNA targets. Generally, an exon inclusion event is promoted if MBNL1 binds 
downstream from an alternatively spliced exon. If MBNL1 binds upstream, an exon 
exclusion event is promoted7. Conserved RNA binding domains called zinc fingers 
enable MBNL1 to bind to its pre-mRNA targets.  
Zinc finger (ZnF) binding motifs are highly conserved throughout many nucleic 
acid binding proteins14. There are two pairs of zinc finger RNA binding motifs within 
muscleblind-like 1. These four zinc fingers are split into two pairs, ZnF1-2 and ZnF3-4. 
Each ZnF pair (1-2 and 3-4) form two distinct RNA binding domains, which are 
separated by a 110 amino acid linker. Each of the four tandem zinc fingers are CCCH 
type (meaning three cysteine residues and one histidine residue) and assist in the 
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chelation of a zinc ion and act like fingers grasping the Watson-Crick face of single-
stranded pre-mRNA transcripts15. In vitro RNA binding experiments reveal that 
MBNL1 selectively recognizes and binds to YGCY (where Ys are pyrimidines, either C 
or U) sequences in its RNA substrates, explaining its high affinity for toxic CUG repeat 
RNA7. It is important to note, zinc fingers 1 and 3 show high sequence similarity as do 
zinc fingers 2 and 4 (Figure 4) 15.  
 
 
 
 
 
Figure 4. (a) Schematic representation of human MBNL1’s zinc finger domains. Boxed 
numbers indicate the length of linker segments. (b) Sequence alignment of tandem ZnF1-2 
and ZnF3-4 tandem zinc finger domains from human MBNL1. The residues involved in the 
chelation of zinc ions are highlighted in blue. Secondary-structure alignment of human 
MBNL1 ZnF (1-2 and 3-4) is shown above the sequences. Numbering above the sequences 
corresponds to human MBNL1 ZnF1-2 and numbering below corresponds to ZnF3-4. (c) 
Crystal structure of the ZnF (1-2) domain, PDB ID: 3D2N. (d) Crystal structure of the ZnF3-
4 domain, PDB ID: 3D2Q. Grey spheres denote zinc ions15. 
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The ZnFs also show high secondary structure similarity apart from an extended 
alpha helix towards the C-terminus of ZnF2 as compared to ZnF415. A complete crystal 
structure of MBNL1 has yet to be determined, but crystal structures of both ZnF1-2 and 
ZnF3-4 exist in isolation (Figure 4).  
Background experiments hint towards the possibility of an RNA-binding protein 
with increased affinity and activity 
Our lab has recently shown that ZnF1-2 and ZnF3-4 RNA-binding domains do 
not possess equivalent splicing activity for MBNL1-regulated splicing events nor do 
they possess equivalent RNA-binding affinities. In the experiment, key residues, 
implicated in the interaction between protein and RNA, were mutated to alanine 
residues, which eliminated the ability to bind RNA targets. These mutations thereby 
resulted in an inactive ZnF domain at the site of mutagenesis enabling us to test the 
activity and affinity of each domain (1-2 and 3-4) individually. A mutation of ZnF3-4, 
producing a mutant MBNL1 containing only an intact, functional ZnF1-2, retained 
about 80 percent splicing activity, as well as 80 percent RNA-binding affinity 
normalized for several tested targets. Conversely, a mutation of ZnF1-2, producing a 
solely functional ZnF3-4 mutant, only retained about 50 percent splicing activity and 40 
percent RNA-binding affinity in comparison to wild type MBNL116.  
These results suggest ZnF1-2 has greater affinity and splicing activity than 
ZnF3-4, which poses the question: Can we engineer an MBNL1 protein with increased 
RNA-binding affinity and splicing activity in comparison to wild type? The idea stems 
from the differences in affinity and splicing activity between the ZnF pairs. Because 
ZnF1-2 exhibits a greater affinity and splicing activity than ZnF3-4, it should be 
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possible to engineer an enhanced MBNL1 with two ZnF1-2 domains. A successfully 
engineered MBNL1 with greater RNA-binding affinity and splicing activity may serve 
as a possible therapeutic protein by either displacing sequestered wild type MBNL1 or 
by more effectively regulating alternative splicing in DM1 patients. The displaced wild 
type MBNL1 could theoretically resume function and alleviate DM1 symptoms by 
rescuing mis-splicing events. Creating these MBNL1 variants also provides a tool to 
study the importance of the ZnF domains to MBNL1 function. 
In order to answer the aforementioned question, two protein constructs were 
engineered. The first construct (WT-MBNL1) represents wild type. WT-MBNL1 
includes both ZnF1-2 and ZnF3-4. The other construct replaces ZnF3-4 with ZnF1-2 to 
generate a double ZnF1-2 MBNL1 or MBNL1 (1-2, 1-2) protein (Hale, M., 
unpublished). Each construct contains a human influenza hemagglutinin (HA) at the N-
terminus for western blot detection (Figure 5). The lab predicted the overall splicing 
activity of the constructs would increase with ZnF1-2 content to produce the following 
trend: MBNL1 (1-2, 1-2) > wild type (WT) MBNL1. To test the splicing activity of 
these proteins, a cell-based splicing assay was utilized. 
In this assay, HeLa cells (immortal cell line derived from a human cervical 
adenocarcinoma) are co-transfected with a reporter minigene and plasmid DNA 
Figure 5. Graphic representation of the two engineered MBNL1 constructs. MBNL1 variants each 
contain an HA tag (brown box). Zinc fingers 1 and 2 and represented by yellow boxes and zinc 
fingers 3 and 4 are represented by purple boxes. 
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containing recombinant WT or synthetic MBNL1 protein. The reporter minigenes are, 
as their name implies, miniature versions of genes that are involved in an alternatively 
splicing event. Each minigene contains an MBNL1-regulated alternatively spliced exon 
flanked by two intervening introns and two neighboring exons. Those tested include the 
insulin receptor (INSR), cardiac Troponin T type 2 (TNNT2), and MBNL1. Following 
co-transfection of the minigene and protein plasmid, the HeLa cells resumed normal 
cellular activity (transcription and translation) and expressed the protein construct from 
the plasmid containing the MBNL1 protein. The cells will also express the MBNL1-
mediated reporter minigene mRNA isoforms. The mRNA isoform product ratio is 
regulated by the overexpressed protein. Due to the high efficiency of the constitutive 
promoter, MBNL1 will flood the system causing an overabundance of the splicing 
factor.  
Once the cells have incubated for 18 hours, the RNA was harvested and 
purified, removing any DNA. The harvested RNA contains the alternatively spliced 
products as well as all other endogenous RNA. Due to RNA’s instability, it must be 
converted to its stable counterpart, DNA. Reverse transcriptase circumvents this 
dilemma by converting the desired RNA, through reporter-specific primers, back into 
complementary DNA (cDNA). After the RNA is converted into cDNA, the cDNA is 
subject to polymerase chain reaction amplification or PCR. Through reporter-specific 
primers, PCR allows for selective amplification of the cDNA of interest. In other words, 
PCR is used to substantially increase the amount of DNA to an amount that is more 
favorable for measurement and management. The PCR samples of the alternatively 
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spliced products are then run on a native gel, using gel electrophoresis, and analyzed 
with imaging. 
Gel electrophoresis distinguishes and separates the alternatively spliced products 
as a function of their size. Larger products, such as those that contain the alternatively 
spliced exon (inclusion products), take longer to migrate through the matrix of the 
acrylamide gel due to their large size. On the other hand, smaller products (exclusion 
products) are able to migrate more quickly through the gel. A difference in migration 
speed causes the larger products to appear higher up on the gel because the exon 
inclusion product contains more nucleotides. The opposite can be said for the exclusion 
product, which appears lower on the gel. Finally, splicing activity can be determined by 
measuring the intensity of the resulting bands. A comparison of percent exon inclusion, 
which is calculated by dividing the intensity of the inclusion band by the sum of the 
intensities of both the inclusion and exclusion bands, provides a means to measure 
splicing activity. Percent exon inclusion is used to measure the splicing activity by 
comparing the percent inclusion of the overexpressed protein samples to the control 
cells’ splicing activity without expression of MBNL1. 
The following minigenes were tested in the above-mentioned manner: MBNL1, 
INSR, hTNNT2, TNNT2, VLDLR, Nfix, and ATP2A1. The results of the overexpression 
assay reveal that MBNL1 (1-2, 1-2) splicing activity is similar to that of wild type, 
achieving an average splicing activity of 114.8% across all tested minigenes normalized 
to WT-MBNL1 (Hale, M., unpublished) (Table 1).  
These results suggest that MBNL1 (1-2, 1-2) is about the same or slightly better 
than wild type at regulating splicing activity. However, this overexpression system 
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provides limited information because only a single data point can be collected. With 
only a single data point of comparison, it is difficult to definitively answer our original 
question: Can we engineer an MBNL1 protein with increased RNA binding affinity and 
splicing activity in comparison to wild type. It is possible that MBNL1 (1-2, 1-2) can 
regulate alternative splicing at lower concentrations of protein in comparison to wild 
type. The overexpression system does not let us confirm that possibility. 
In order to more 
definitively answer our original 
question, it is necessary to 
compare splicing activities as a 
function of protein concentration. 
Unfortunately, few models are 
available that test splicing 
activity response in regards to the 
concentration of the splicing 
factor. This research aims to 
develop a simple dosing system 
in which the splicing activity 
(% exon inclusion) can be determined over a wide range of protein (MBNL1) 
concentrations. Such a model will theoretically measure the splicing activities as a 
function of the construct concentration and provide a more accurate comparison in 
splicing activities not possible with an overexpression assay. 
Table 1. Percent splicing activity across all 
seven tested minigenes normalized to WT-
MBNL1 
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METHODS 
A modification of the cell-based splicing assay as described earlier will be 
utilized (workflow shown in Figure 6 and described in Purcell, et al). However, this 
model will address some of the pitfalls associated with an overexpression assay. Instead 
of transfecting the full concentration of protein plasmid (200 nanograms), varying 
amounts of protein plasmid (ranging from 0 to 200 nanograms) will be transfected, 
creating a titration-like effect. A titration of protein plasmid ranging from a low 
concentration to the full concentration will enable us to determine the splicing activity 
at varying concentrations of protein. The sensitivity of a splicing event to each of the 
protein constructs’ concentration will help answer our original question and offer a 
simple alternative to other dosing methods. In this study, we investigate the constructs’ 
Figure 6. Workflow illustration of a transfection titration cell-based splicing assay. Circles 
represent plasmid vectors. Colored boxes (grey and orange) represent exons 4,5, and 6 of the 
MBNL1 minigene. Purple arrows represent exon-specific PCR primers. 
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splicing efficacy in the auto-regulation of exon 5 exclusion of its own pre-mRNA 
transcript. 
Cell culture and transfection 
HeLa cells are routinely cultured as a monolayer in Dulbecco’s Modified Eagle 
Medium (DMEM high glucose with GlutaMAX™, Life Technologies) supplemented 
with 10% fetal bovine serum (FBS)  at 37°C under 5% CO2 to approximately 85-90% 
confluence. Prior to transfection, the cells were plated in twelve-well plates at a density 
of 8x104 cells/well. Plated cells are grown for approximately 36 hrs in DMEM, after 
which they are washed with 1X PBS (phosphate buffered saline) and the DMEM is 
replaced with Opti-MEM®  reduced serum media (Life Technologies) and transfected 
with 400 ng total of plasmid DNA using Lipofectamine 2000® (Life Technologies) as 
described by the manufacturer's protocol. In each of the samples, cells are transfected 
with 200 ng of MBNL reporter minigene plasmid in addition to 200 ngs of a 
combination of construct protein plasmid and empty pCI vector plasmid. Control 
samples (mock) are transfected with 200 ngs of empty pCI vector. The remaining 
samples are transfected with 5, 10, 15, 20, 25, 30, 40, 50, 70, 90, and 200 ngs of 
construct protein plasmid to create a titration range. Empty pCI vector is transfected in 
these samples to keep the total concentration of DNA transfected constant at 400 ng (5 
ng of protein plasmid and 195 ng of empty plasmid for example). Cells were harvested 
with TrypLE (Invitrogen) 24 h after transfection and pelleted via centrifugation. 
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Western blot analysis 
HeLa cell pellets were lysed in radioimmunoprecipitation assay (RIPA) buffer 
(50mMTris, pH 7.4, 150mMNaCl,1% NP-40, 0.25% sodium deoxycholate, 0.1% SDS, 
1 mM phenylmethylsulfonyl fluoride [PMSF]) supplemented with 1X protease inhibitor 
cocktail (SigmaFAST; Sigma) prior to resolution on 10% SDS-PAGE gels. MBNL1 
construct proteins were probed with 1:1,000 primary antibody (anti mouse), followed 
by 1:1,000 goat anti-rabbit secondary. The GAPDH loading control was probed using 
GAPDH primary (1:1,000) antibody (anti rabbit) followed by 1:1,000 goat anti-mouse 
secondary. Fluorescence was visualized and quantified using a LI-COR imaging system 
(LI-COR Biosciences). 
 
Cell-based splicing assay 
RNA was isolated from HeLa cell pellets using an RNeasy kit (Qiagen). Isolated 
RNA (500 ng) was incubated with 1 unit of RQI DNase (Promega) in a 10 µl reaction 
mixture for 1 h at 37 °C. After DNase treatment, RNA (100 ng) was reverse transcribed 
(RT) in a 10 µl reaction volume with Superscript II (Invitrogen), according to the 
manufacturer’s protocols, using reporter-specific primers for 50 min at 42 °C. The 
resulting cDNAs (2-µl volumes) are then amplified via polymerase chain reaction 
(PCR) in a 20-µl reaction mixture using flanking exon-specific primers16. The number 
of amplification cycles was determined to be within the linear range for the primers 
used. The resulting PCR products were resolved by gel electrophoresis on 6% native 
polyacrylamide (19:1) gels run at 300 V for 90 min. Alternatively spliced products were 
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visualized and quantified using SYBR green I nucleic acid stain (Invitrogen) in 
combination with an AlphaImager HP system (Alpha Innotech). Bands representing 
alternatively spliced products are quantified using Alpha Imager HP software (Alpha 
Innotech), and percent exon inclusion is calculated as the ratio of the intensity of the 
inclusion band to the sum of the intensities of inclusion and exclusion bands. 
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Figure 7. Western blot analysis. (a) Qualitative confirmation of dosing system for both WT-MBNL1 
and MBNL1 (1-2, 1-2). (b) Quantification of WT-MBNL1 protein concentration calculated as the 
relative fluorescence normalized to GAPDH. (c) Quantification of MBNL1 (1-2, 1-2) protein 
concentration. Values are reported as an average of three separate western blots. 
RESULTS 
Western blot analysis confirms successful dosing 
Western blot analysis was performed to confirm the effectiveness of the dosing 
experiment. In this experiment, HeLa cells were co-transfected with a titration of the 
construct protein plasmid at 0, 5, 10, 15, 20, 25, 30, 40, 50, 70, 90 and 200 nanograms 
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Figure 8. Western blot quantification of an 
overexpression of the constructs in HeLa 
relative to GAPDH. 
 
and a constant concentration of 
MBNL1 reporter minigene (200 ng). 
A qualitative assessment of the 
western blot reveals a direct 
correlation between the 
concentration of the construct 
protein plasmid transfected and the 
concentration of the construct 
protein expressed within the cells 
(Figure 7). The concentration of 
protein expressed in vivo increases 
as the amount of the plasmid 
transfected increases, thus, 
confirming a successful dosing 
system.  
Regardless of the positive qualitative results, the western blot does not fully 
encompass our goals. The original goal of this dosing model was to compare splicing 
activities between two splicing factors, one wild type and one engineered. In order to 
compare the activities between the two splicing factors, it is necessary to determine a 
relationship between the transfected plasmid amount and the concentration of construct 
protein expressed. However, we cannot directly cross compare protein concentrations as 
a function of the amount of plasmid transfected because of differences in protein 
expression of the plasmid system. This issue becomes apparent in the western blot 
WT 
Figure 8. Western blot quantification of an 
overexpression of the constructs in HeLa relative 
to GAPDH. 
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quantification of protein levels in the original overexpression assays performed. Here 
western blot analysis revealed that the concentration of MBNL1 (1-2, 1-2) is 
significantly lower (about half) than that of WT-MBNL1 in an overexpression system 
when the same amount of plasmid was transfected (Hale, M., unpublished) (Figure 8). 
Therefore, it is necessary to accurately determine the protein concentration at each 
“dose” for each construct. 
Quantitative analysis reveals that the range of protein plasmid concentration (0-
200 ng) creates an effective range of protein expression levels. According to the data, a 
near 100-fold range in construct protein concentration was achieved from the smallest 
transfected amount (5 ng) to the largest (200 ng) in each of the constructs (Figure 7). 
Unfortunately, the accuracy and reproducibility of the quantitative western blots pose a 
concern for a quantitative analysis. Performing multiple western blots under consistent 
conditions and with the same samples results in significantly different concentration 
values (represented by normalized fluorescence). In some occasions, the same sample 
(dose) subject to the same protocol produced up to a two-fold difference in construct 
protein concentrations expressed (data not shown). Therefore, technical reproducibility 
issues were an obstacle in western blot quantification. Due to the technical issues with 
the system, it is difficult to cross-compare blots. These inconsistencies within the same 
sample can likely be attributed to limitations inherent to quantitative western blot 
analysis. As it stands, the technology does not yet exist for quantitative purposes in 
westerns, although western blots serve qualitative purposes quite well. 
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Both WT-MBNL1 and MBNL1 (1-2, 1-2) exhibit a splicing sensitivity response 
In order to determine the splicing activities of each construct at varying 
concentrations, an RT-PCR splicing assay was performed. Once again, HeLa cells were 
transfected with a construct protein plasmid titration of 0 (mock), 5, 10, 15, 20, 25, 30, 
40, 50, 70, 90, and 200 nanograms, and were accompanied by the MBNL reporter 
minigene. Twelve data points of exon 5 percent exclusion, (splicing activity) 
corresponding to each dose, were generated to highlight the splicing response to the 
individual constructs. WT-MBNL1 was performed in at least a triplicate (n=4 for 0-30 
ngs, n=3 for 40-200 ngs) and MBNL1 (1-2, 1-2) was performed in duplicate. Some of 
the bands in the lanes failed to appear. Reprocessing the RNA and re-running it on a gel 
allowed us to recover the “missing bands” (data not shown). Human error or reverse 
transcriptase complications may account for the missing bands in the original gels.  
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Figure 9. Splicing assay analysis. (a) Dosing response to both WT-MBNLl and MBNL1 (1-2, 
1-2). The numbers below the splicing gels are actual exon 5 percent inclusion values. (b) An 
overlapping of both constructs’ splicing response curves.  
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According to the splicing results, a direct correlation between splicing activity as 
measured by exon 5 percent inclusion and protein levels as detected by western blots 
was observed. As the amount of plasmid transfected increases, the percent of exon 5 
inclusion decreases – corresponding to an increase in splicing activity (Figure 9). In 
response to overexpression (the maximum amount of protein plasmid, 200 ng) and in 
the absence of protein plasmid (mock), the exon 5 exclusion event of MBNL shows 
similar activity between WT-MBNL1 and MBNL1 (1-2, 1-2). For both constructs, the 
splicing activity appears to saturate near 16-20 percent inclusion, 14.63% ±3.84 for 
WT-MBNL1 and 21.09% ±2.70 for MBNL1 (1-2, 1-2).The endogenous (mock) splicing 
activity sits near 65 percent inclusion, 63.30% ±2.63 for WT-MBNL1 and 70.90% 
±5.35 for MBNL1 (1-2, 1-2). These data coincide with the original overexpression 
assays (Hale, M., unpublished). Additionally, this titration dosing system offers ten 
extra data points, in which one can compare the splicing activity response sensitivity 
between both constructs. For each of the constructs, the percent inclusion of exon 5 is 
plotted against the amount of the plasmid transfected in an effort to compare efficacy of 
the proteins. Figure 9 depicts the degree of sensitivity by the slope of the response. 
According to Figure 9, splicing activity is at least the same or greater for MBNL1 (1-2, 
1-2) at the same amount of transfected protein plasmid in comparison to WT-MBNL1.  
A comparison of EC50 – effective amount of protein plasmid at which half of 
splicing activity (halfway point of percent exon inclusion between percent exon 
inclusion at 0 ng and 200 ng) is achieved – values between the two constructs suggests 
that MBNL1 (1-2, 1-2) regulates the exclusion of exon 5 much more effectively than 
WT-MBNL1. MBNL1 (1-2, 1-2) has an EC50 value of approximately 10 to 15 
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nanograms of plasmid versus an EC50 value of approximately 40 to 50 nanograms for 
wild type. However, as mentioned previously, a direct comparison of activity between 
the two constructs that only considers the transfected plasmid amount and neglects the 
actual protein concentration is inaccurate. Across constructs, this comparison fails to 
adequately address the discrepancies between plasmid amount and actual protein 
expression levels. Without a direct correlation between the two concentrations (plasmid 
and protein), the activities of the constructs cannot be accurately compared as a function 
of protein concentration like we hoped to achieve. 
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DISCUSSION 
Western blot analysis and splicing assay results confirm successful dosing 
simulation 
The main goal of this research was to develop a simple model in which a 
splicing activity response can be measured across a wide range of protein 
concentrations. Utilizing a titration of protein plasmid produced a measurable splicing 
activity response with two different proteins, WT-MBNL1 and MBNL1 (1-2, 1-2). This 
achievement is observable in both the western blot and the splicing assay results. The 
western blot analysis reveals that increasing the amount of transfected protein plasmid 
translates to an increase in protein expression levels. With the range of plasmid 
concentration transfected (0-200 ng), we were able to generate a 100-fold increase in 
protein expression (5 ng to 200 ng), which offers a generous range to analyze the 
sensitivity in splicing activity response. This titration created ten additional data points 
that contributed to a more thorough analysis in comparison to an overexpression assay. 
For both proteins studied, an increase in transfected protein plasmid correlates to an 
increase in splicing activity (measured by a decrease in exon 5 % inclusion of the 
MBNL1 transcript). 
Applications and advantages of this dosage simulation model (transfection 
titration) 
The model outlined in this experiment expands upon an overexpression assay. 
Limitations of an overexpression assay, which only generate a single data point, are 
addressed through multiple transfections of varying protein plasmid amounts. Of note, 
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the concentrations selected for this experiment were optimized for a single splicing 
event, exon 5 exclusion of MBNL1. These same concentrations (0, 5, 10, 15, 20, 25, 30, 
40, 50, 70, 90, and 200 nanograms) are not fixed and can easily be manipulated to 
optimize a range specialized to any splicing event. Each of these doses denote a 
reproducible and specific splicing activity (exon 5 percent inclusion), which is 
illustrated by small standard deviation values – a maximum standard deviation of 10.88, 
which would likely reduce had the experiment been performed in triplicate for MBNL1 
(1-2, 1-2) (as opposed to only two independent splicing experiments).  
This model also leaves room for additional data points. Although our 
experiments were performed in twelve-well plates, generating twelve data points 
(including endogenous splicing activity and overexpression splicing activity), a slight 
change in protocol may accommodate plates with a greater number of wells thus 
producing more than twelve data points. The greater the number of data points 
analyzed, the better the representation of splicing activity response. Therefore, this 
model imitates an inducible gene expression system that can be tightly controlled. 
However, the model outlined in this experiment is not the only inducible gene 
expression system that exists.  
Recently, an inducible gene expression system has been developed that takes 
advantage of the Tet-On advanced transactivator and the PTight inducible reporter. In the 
presence of doxycycline (dox), Tet-On Advanced binds to the tetracycline response 
element (TREMod) in PTight, and produces high-level transcription of the downstream 
gene of interest17. As a result, this system allows for a method to control gene 
expression as a function of dox concentration. Some of the benefits of this system 
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include extremely tight regulation, high specificity, high inducibility, and fast response 
times. However, one pitfall of this system is the time it takes to generate a stable, 
inducible cell line that is required for a Tet-On Advanced induction system. A 
functioning inducible cell line can take upwards of a few months to create18, whereas 
the system outlined in this experiment can be completed from start to finish in just short 
of a week (around 5-6 days). Despite the dox dosing system boasting greater precision 
and tighter control, both methods, although they take different approaches, achieve 
similar results. This transfection titration method however, can produce results in a 
fraction of the time. Therefore, the model outlined in this experiment is useful under 
time constraints and allows for quick splicing sensitivity analysis. This model can also 
be used in conjunction with the dox system to provide further support of results. 
Challenges faced in developing the transfection titration model 
Unfortunately, the experiments did not definitively answer one of our questions: 
Can we engineer an MBNL1 protein with increased RNA-binding affinity and splicing 
activity in comparison to wild type? Firstly, an overexpression assay fails to answer this 
question because it is possible that MBNL1 (1-2, 1-2) regulates alternate splicing at 
lower concentrations than WT-MBNL1. In order to answer this question, we need to 
compare the splicing activities of the constructs at varying concentrations under the 
assumption that a concentration of transfected plasmid corresponded to the same 
concentration of active protein. What we failed to anticipate was that transfecting the 
same amount of protein plasmids resulted in vastly different expression levels between 
the constructs, as shown in previous western blot quantifications of the overexpression 
assays. 
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Ideally, we could eliminate this inconsistency by determining a relationship 
between the amount of plasmid transfected and the concentration of protein expressed 
for each construct. Instead of comparing the splicing activities as a function of plasmid 
transfected, we could compare the splicing activities as a function of actual protein 
concentration with the previously mentioned relationship. Determining this relationship 
would provide us with an accurate comparison of splicing activities between the 
constructs. Western blot quantification is necessary to determine such a relationship. 
However, the effort to determine the relationship between plasmid concentration and 
protein concentration was thwarted by accuracy limitations inherent in western blot 
quantification. A lack of reproducibility within the same samples poses an obstacle in 
accurately defining a relationship because in some cases the relative fluorescence 
between technical replicates can differ by up to a factor of two. Until western blot 
quantification accuracy and reproducibility improve, it is not possible to accurately 
determine protein concentrations for quantitative analysis. This model successfully 
depicts the sensitivity of the splicing event to a specific construct as a function of 
plasmid concentration. However, without an accurate correlation between plasmid 
concentration and active protein concentration, this model ultimately fails to cross-
compare construct splicing activities.  
Another smaller issue that this experiment encountered was “missing bands.” In 
some experiments, either very faint or absent bands were observed in some of the lanes. 
This issue suggests there was an insufficient quantity or concentration of DNA loaded 
on the gel. A lack of DNA can likely be attributed to a failure of the reverse 
transcriptase enzyme (without conversion of the RNA into cDNA, there is no DNA to 
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PCR amplify thus resulting in no bands) or perhaps human mixing error. The missing 
bands could be recovered by subjecting the same RNA to another round of processing 
(DNAse then RT-PCR). Recovered bands produced percent inclusion values in 
agreement with other independent splicing experiments.  
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FUTURE DIRECTIONS AND REFINEMENT 
In short, this novel model is simple to use, versatile, hosts a wide range of 
applications, and simulates an inducible gene expression system. The model outlined in 
this experiment can also be performed relatively quickly, especially in comparison to 
other inducible gene expression systems such as the dox system. Importantly, this 
model expands on an overexpression system and provides a more accurate 
representation of splicing activity sensitivity by providing more than one data point of 
comparison. As previously mentioned, this model falls short in comparing activities 
between proteins due to limitations in western blot quantification. 
A refinement of this model could theoretically erase the reproducibility 
limitations of western blots. For example, the overall trend of increasing plasmid 
concentration to increasing protein expression levels held within each western blot, but 
the magnitudes of the values were difficult to reproduce. For this reason, I propose 
performing the same experiment but instead first harvesting the RNA (for the splicing 
assay) and protein (for western blot analysis) from the same HeLa cells in a single 
experiment for both WT-MBNL1 and MBNL1 (1-2, 1-2). Then, unlike before, I plan to 
perform a western blot analysis of both constructs at the same time. This ensures that 
both of the constructs are subject to the same sources of error. Also dissimilar to 
previous experiments, I will perform a western blot analysis and splicing assay from the 
same cells (previously performed from separate cell passages), which will further 
eliminate sources of inconsistency.  
Theoretically, quantifying both constructs in the same blot should eliminate the 
inconsistencies inherent in western blot quantification. A relationship between plasmid 
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concentration and active protein concentration could then be more reliably determined. 
Finally, with the relationship determined, we can cross compare the splicing activities 
of our proteins of interest. 
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